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ABST RACT
Thiamine pyrophosphate (TPP) is the phosphorylated and active form of thiamine (Vitamin B1). We 
hypothesized that the administration of thiamine in its immediately available active form could provide the 
metabolic pathways for a supplement able to promote the metabolism of ketoacids and to reduce lactate 
accumulation in exercising horses. Ten horses were conditioned for 20 days to daily standardized exercise. 
All horses underwent a first “stress test” (ST) consisting in 1,200 meters at maximum speed on track, and 
were checked before and after for clinical and clinical pathology parameters. After the ST, the same animals 
were administered TPP (Bicarbossilasi®, Teknofarma S.p.A., Torino, Italy), 1 mg/Kg b.w., I.V., twice daily 
for seven days. At the end of treatment, a second stress test (STTPP) was performed. Post-exercise serum 
lactate concentration resulted in significantly lower levels (p< 0.05) after treatment with TPP (ST vs STTPP). 
These data suggest that supplementation with thiamine in its active form improves glucose metabolism and 
prevents lactate accumulation in muscle, enhancing aerobic capacity and metabolic pathways of glucose 
utilization during exercise. 
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INTRODUCTION
Vitamin B plays an important role in energy metabolism and 
is considered a key nutrient in exercising horses (1). Thiamine 
pyrophosphate (TPP) is the phosphorylated and activated 
form of thiamine (Vitamin B1). The activation of thiamine 
occurs primarily in the liver with ATP consumption, and 
once phosphorylated, the molecule acquires the active form 
as TPP. All living organisms needs thiamine, but only bac-
teria, fungi, and plants are able to synthesize it. Thiamine is 
an essential nutrient for animals and humans, and must be 
obtained from the diet or through metabolic production by 
gut microorganisms (2).
TPP mainly acts as coenzyme for the decarboxylation 
of ketoacids and plays an essential role in the oxidative de-
carboxylation of pyruvate, allowing the formation of acetyl 
coenzyme-A under aerobic condition. The latter will enter 
in the Krebs cycle to allow for energy production (1). Since 
pyruvate is derived from glucose, it should be emphasized 
that the energy drive from glucose oxidation is highly de-
pendent upon TPP (3).
During short and intense efforts, especially in the most 
energy demanding tissue such as muscles, an excess of py-
ruvate is produced as the final product of glycolysis and can 
be converted to lactic acid (4). The excess of lactic acid is 
transferred into the blood and reaches the liver where it is 
converted back to pyruvate and then glucose (Cori cycle) (4). 
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If the effort is continuous, active muscles may fail to transfer 
the excessive lactic acid into the blood, which contributes to 
symptoms of “fatigue” due to the alteration of the physiologi-
cal pH of the cells.
The term “fatigue” indicates a clinical condition of athletic 
horses causing the interruption of exercise or a reduction in 
its intensity (5). In case of high-intensity exercise, fatigue 
is caused by the accumulation of catabolites in blood and 
muscle which affects the contractile capacity of myocytes (6). 
It is evident that as the threshold for “fatigue” increases, the 
improvement in the performance of the horse will increase 
as well. Studies in human athletes demonstrated that fatigue 
can be delayed and performance enhanced if blood glucose 
levels are maintained by oral or intravenous supplementation 
of glucose (7). Given the crucial involvement of thiamine in 
glucose metabolism and the aerobic pathway, particularly in 
the muscles, its importance is evident during exercise and in 
the onset of “fatigue” (1).
Thiamine deficiency can cause neurologic disorders and 
thiamine supplementation can relieve symptoms or resolve 
several neurologic diseases in cats (8, 9), dogs (10), cows (11, 
12) and humans (13, 14). Reduction in serum lactate concen-
tration has also been observed in pigs after TPP administra-
tion (15). Cocarboxylase was found to be beneficial in the 
ischemic canine myocardium due to its favorable systemic 
hemodynamic effects (16).
The effect of thiamine administration has been tested 
in human athletes with different results. In some studies 
thiamine was able to reduce serum lactate concentration 
and to improve resistance to fatigue (17, 18). On the other 
hand, other surveys did not obtain similar results (19, 20). 
A previous study in athletic horses has shown that the oral 
administration of supplemental thiamine decreased the levels 
of serum lactate during exercise (21).
Thiamine pyrophosphate is the active ingredient of the 
veterinary drug Bicarbossilasi® (Teknofarma S.p.A., Torino, 
Italy). In the present study, the effect of thiamine pyro-
phosphate administration to athletic horses during intense 
exercise has been tested in a clinical, cross over trial.
MATERIALS AND METHODS
Animals
Ten pleasure horses (6 male and 4 female) normally used for 
recreational riding (e.g. trail riding) were included in the study. 
Breeds of horses included four Sella Italiano, three Anglo-
Arabian, two Murgese and one Tolfetano. All horses were 
active at the time of the study. The age of the horses ranged 
from 4 to 21 year (mean: 10.6 ± 6.0 years), and their weight 
ranged from 407 to 600 Kg (mean: 495.2 ± 57.3 Kg). All 
animals, once included in the study, were stabled in boxes and 
subjected to a standardized diet: hay and water ad libitum and 
integrated with complementary feed corresponding to about 
1% of their body weight divided into two daily rations. Clinical 
assessment was performed daily to check for any symptoms 
that could cause withdrawing the animals from the study.
Study design 
Before starting the study, the animals were conditioned for 
20 days to daily standardized training sessions lasting 35 
minutes and consisting of a warming-up phase (walk for 
10 minutes), followed by 5 minutes trot, 5 minutes gallop, 5 
minutes trot and 10 minutes walk.
At the end of the 20 days, the horses underwent their 
first stress test (ST): 400 meters walk followed by 800 meters 
trot; the horses then performed an exercise at their maximum 
potential (maximum speed) for 1,200 meters. Clinical and 
clinical pathology evaluations were performed before (T0) 
and immediately after (T1) the ST. The post-stress evalua-
tions were made directly on the track immediately after each 
horse had stopped.
Starting from the first day, the administration of TPP was 
commenced, at the dose of 1 mg/Kg b.w., I.V., twice a day 
and continued for seven days. At the end of the administra-
tion period, the horses underwent a second stress test (STTPP) 
with the same protocol previous described and with clinical 
and clinical pathology evaluation as previously performed (at 
T0TPP and at T1TPP). 
The horses were ridden by the same rider during both 
ST and STTPP.
Sampling and clinical pathology evaluations
Venous blood samples were collected from the jugular vein 
into sterile tubes with and without ethylene diaminetetraacetic 
acid (EDTA) at T0, T1, T0TPP and T1TPP and maintained 
at 4°C until the delivery to the laboratory within 3 hours 
from collection. The following hematologic and biochemi-
cal parameters were measured within 12 hours from sample 
collection: erythrocytes (red blood cells, RBC), packed cell 
volume (PCV), hemoglobin (Hb), red cell distribution width 
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(RDW), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concen-
tration (MCHC), total leukocytes, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils and platelets along with 
PDWc (platelet distribution width) and MPV (mean platelet 
volume) (Cell Dyn 3500, Abbott, Chicago, IL, USA). 
The biochemical profile included aspartate aminotrans-
ferase (AST), gamma glutamyltransferase (GGT), creatine 
phosphokinase (CPK), total protein (TP), albumin (Alb), 
urea, creatinine (Crea), glucose (Glu), alkaline phosphstase 
(ALP), lactate dehydrogenase (LDH), total bilirubin (TB), 
direct bilirubin (DB), triglycerides (Tryg), cholesterol (Chol), 
calcium, phosphorus, magnesium, sodium, potassium, and 
chlorine (Targa 3000 plus, Biotecnica Instruments, Italy, 
Rome).
Blood lactate was analysed using a portable device 
(Accutrend® Plus, Roche, Mannheim, Germany) at T0, T1, 
T1+2h, T1+8h, T1+18h, T0TPP, T1TPP, T1TPP+2h, T1TPP+8h, 
T1TPP+18h.
Statistical analysis
All results are expressed as the mean value and standard devia-
tion (SD) for each stage of the test. Data collected at T0 and 
T1 were compared with those obtained at T0TPP and T1TPP, 
respectively, by the Student’s t-test. For serum lactate, the com-
parison was performed between each sampling stage before 
(T0, T1, T1+2h, T1+8h, T1+18h) and after (T0TPP, T1TPP, 
T1TPP+2h, T1TPP+8h, T1TPP+18h) thiamine administration. 
P value for statistical significance was set at <0.05 for 
all tests. Statistical analyses were performed using the 
WINPEPI (PEPI-for-Windows) computer programs (22).
RESULTS
None of the horses showed clinical signs that could result in 
withdrawal from the study. Values for clinical and laboratory 
data at different stage of the study and normal ranges (23, 24, 
25, 26, 27) are reported in Tables 1, 2, and 3. 
Statistically significant differences (P < 0.05) between T0 
Table 1. Mean value for haematological parameters before and after the first (ST) and the second (STTPP) stress test.
ST STTPP Normal range
Paramether T0
Mean (SD)
T1
Mean (SD)
T0TPP
Mean (SD)
T1TPP
Mean (SD)
WBC (x103/µl) 9.5* (2.1) 9.2 (2.1) 8.7* (1.4) 9.5 (1.8) 5.6-12.1
LYM (x103/µl) 3.3 (2.2) 3.6 (1.9) 3.2 (1.8) 3.3 (1.8) 1.2-5.1
MON (x103/µl) 0.5 (0.3) 0.5 (0.4) 0.2 (0.2) 0.4 (0.4) 0-0.7
NEU (x103/µl) 5.1 (1.0) 4.5 (1.2) 4.7 (1.0) 5.2 (1.5) 2.9-8.5
EOS (x103/µl) 0.6 (0.2) 0.5 (0.2) 0.5 (0.2) 0.6 (0.4) 0-0.8
BAS (x103/µl) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0-0.3
LYM% 32.8 (13.0) 37.5 (13.2) 35.1 (13.3) 34.2 (15.0) 17-68
MON% 5.7 (3.9) 5.5 (3.1) 3.0 (3.1) 4.0 (3.4) 0-14
NEU% 54.5 (11.6) 50.4 (11.9) 55.1 (10.9) 54.6 (12.2) 22-72
EOS% 6.3 (2.8) 5.9 (2.6) 5.9 (2.8) 6.5 (3.6) 0-10
BAS% 0.8 (0.3) 0.8 (0.4) 0.8 (0.4) 0.8 (0.4) 0-4
RBC (x106/µl) 8.9 (0.9) 8.8 (0.7) 8.7 (0.7) 9.3 (2.6) 6-10.4
HGB (g/dl) 13.8 (1.6) 13.6 (0.9) 13.8 (1.1) 14.8 (4.9) 11-19
HCT % 40.1 (4.3) 40.2 (3.5) 39.9 (3.0) 43.0 (13.0) 32-53
MCV (fl) 45.4 (2.4) 45.6 (2.6) 45.8 (2.3) 46.1 (2.1) 37-49
MCH (pg) 15.6 (0.7) 15.4 (0.7) 15.9 (0.8) 15.8 (0.8) 13.7-18.2
MCHC (g/dl) 34.5 (1.0) 33.9 (1.5) 34.7 (1.6) 34.2 (1.1) 31.0-38.6
RDWc % 21.1 (0.5) 21.4 (0.6) 21.2 (0.6) 21.6 (0.8) 18-23
PLT (103/µl) 178.8 (28.9) 182.9 (32.4) 171.8 (40.6) 192.1 (57.1) 117-256
PCT% 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0-0.1 
MPV(fl) 7.3 (0.8) 7.5 (0.6) 7.5 (0. 5) 7.2 (0.7) 5.4-9.3
PDWc% 34.1* (1.7) 36.8 (1.8) 36.8* (2.3) 36.0 (1.9) 26-70
*=P< 0.05
Research Articles
Published in IVIS with the permission of the editor Close window to return to IVIS
Israel Journal of Veterinary Medicine  Vol. 72 (2)  June 2017Laus, F.18
and T0TPP were found for WBC, PDW, AST, BUN, P, Na, 
and Mg. Differences between T1 and T1TPP were found for 
AST, BUN and Mg. ALP was found to be slightly higher 
than normal range at T0.
CK was found to be increased between ST and STTPP 
but the difference was not statistically significant. Lactate 
dehydrogenase (LDH) was found to be higher than normal 
ranges in all stage of the study. For lactate concentration 
differences were found between T1 and T1TPP but not for 
the other sampling times. 
DISCUSSION
The reason for the declines of total WBC count and the 
increased PDW at rest after administration of TPP are not 
clear. In both cases, however, the values fell within the normal 
physiological ranges (24). The lower WBC number may be 
due to the decrease of the influence of the stress, since the 
horses were more accustomed to be handled and sampled 
after the first session. The authors can provide no explana-
tion for the differences in PDW measurement (an index of 
platelet size uniformity), although change in blood coagula-
Table 2. Mean value for biochemical parameters before and after the first (ST) and the second (STTPP) stress test.
ST STTPP Normal
Range
Paramether T0
Mean (SD)
T1
(Mean (SD)
T0TPP
Mean (SD)
T1TPP
Mean (SD)
AST (U/l) 315.1 (69.8)* 289.9 (33.0) * 266.9 (89.4)* 282.4 (60.2) * 160-412
LDH (U/l) 716.5 (163.0) 631.1 (142.1) 756.7 (153.9) 719.8 (180.7) 162-412
ALP (U/l) 412.8 (176.1) 375.9 (102.9) 362.0 (87.9) 370.3 (83.6) 143-395
GGT (U/l) 23.9 (15.2) 20.9 (10.3) 19.7 (8.0) 20.1 (6.5) 6-32
CK (U/l) 286.6 (111.4) 292.1 (76.4) 521.1 (53.1) 434.3 (39.5) 60-330
BUN (mg/dl) 30.7 (7.8) * 28.4 (7.1) * 21.6 (5.1) * 21.7 (5.3)* 11-27
CREA (mg/dl) 1.1 (0.2) 1.2 (0.2) 1.2 (0.1) 1.3 (0.1) 0.4-2.2
PROT (g/dl) 7.4 (0.3) 7.4 (0.3) 7.4 (0.6) 7.2 (0.5) 5.6-7.6
ALB (g/dl) 3.3 (0.2) 3.4 (0.2) 3.3 (0.2) 3.2 (0.2) 2.6-3.7
GLOB (g/dl) 4.1 (0.4) 4.0 (0.3) 4.1 (0.5) 3.9 (0.5) 2.6-4.1
Alb/Glob 0.8 (0.1) 0.9 (0.1) 0.8 (0.1) 0.8 (0.1) 0.6-1.4
BT (mg/dl) 1.7 (0.4) 2.1 (0.7) 2.1 (0.7) 2.1 (0.7) 0-3.2
B Dir (mg/dl) 0.2 (0.0) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2) 0-0.4
B Indir (mg/dl) 1.5 (0.4) 1.8 (0.6) 1.8 (0.8) 1.9 (0.8) 0.2-2.0
GLUC (mg/dl) 77.6 (10.1) 88.4 (10.6) 83.9 (11.9) 81.1 (4.7) 62-134
TRIG (mg/dl) 19.4 (4.8) 20.7 (7.7) 22.2 (7.2) 22.3 (9.3) 4-44
CHO (mg/dl) 80.7 (11.3) 77.8 (9.6) 75.5 (11.4) 73.2 (11.6) 75-150
Ca (mg/dl) 11.9 (0.9) 11.6 (1.2) 11.7 (0.5) 11.1 (0.5) 10.2-13.4
P (mg/dl) 2.8 (1.1)* 3.2 (0.9) 3.7 (0.7)* 3.8 (0.8) 1.5-4.7
Na (mg/dl) 133.8 (4.2)* 133.9 (4.0) 131.2 (1.7)* 132.8 (1.6) 128-142
K (mg/dl) 3.9 (0.4) 3.8 (0.4) 3.8 (0.3) 4.0 (0.5) 2.9-4.6
Cl (mg/dl) 101.2 (5.2) 100.6 (4.6) 100.3 (3.3) 99.8 (2.9) 98-109
Mg (mg/dl) 1.6 (0.2)* 1.4 (0.3)* 2.3 (1.0) * 2.0 (0.8)* 1.4-2.3
*= P< 0.05
Table 3. Mean value of lactate serum concentration before and after the first (ST) and the second (STTPP) stress test.
ST STTPP
T0
Mean (SD)
T1
Mean (SD)
T1+2h
Mean (SD)
T1+8h
Mean (SD)
T1+18h
Mean (SD)
T0TPP
Mean (SD)
T1TPP
Mean (SD)
T1TPP+2h
Mean (SD)
T1TPP+8h
Mean (SD)
T1TPP+18h
Mean (SD)
Serum lactate
concentration 2.1 (4.0) 11.4* (6.1)
2.6 
(4.5)
1.6 
(3.9)
1.7
(4.1) 2.0 (3.9) 9.8* (5.6)
2.2
(4.2)
1.6
(3.9)
1.5
(3.9)
*=P< 0.05
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tion and platelet indexes has been shown to be induced by 
exercise in athletic horses (28). Variations of AST, BUN, P, 
Na and Mg at different stages of the study (mainly when 
dosed at rest conditions, e.g. T0 and T0TPP) can be considered 
as normal oscillation within their normal physiological ranges 
(23, 26). Regarding BUN, the ranges reported in literature 
are highly variable, ranging from 11-27 mg/dl (23) to 24-48 
mg/dl (27). Furthermore, also the values recorded at T0 and 
T1 in the present study can be considered within the normal 
range for athletic horses, since it is known that exercise can 
cause about a 60% increase in this value (23). Elevation in 
alkaline phosphatase (ALP) activity is considered a marker 
of liver diseases or exhaustion syndrome in horses (23, 29). 
However, the slight increase of ALP found at T0 was not 
associated with clinical or laboratory evidence of liver injures 
(e.g. increased AST or GGT) or exhaustion. Since several tis-
sues contain ALP (bone, intestine, placenta, leukocytes) (30) 
this slight increase could be due to factors not specifically 
related with the study and not clinically relevant to the aims.
CK was found to be increased at STTPP, although without 
statistical significance. Increases in CK are used to detect 
muscular or cardiac damage but none of the horses showed 
signs of muscular discomfort or cardiac insufficiency dur-
ing the trial. Values about 500 U/l are considered normal in 
exercising horses (31) and only large increases of CK value 
are usually considered of clinical significance (23). Muscle 
cells are able to release significant quantities of CK without 
necessarily being damaged (31) and recumbency or shiver-
ing can account for slight rise in CK level in serum (22). 
Moreover, the differences in CK found in the present study, 
could be due to causes not related to the vitamin administra-
tion, such as the short half life in blood (32), the instability 
when stored (23) or the hemolysis normally induced by the 
sampling technique (33).
Lactate dehydrogenase (LDH), as other muscular en-
zymes in horses in training, normally can be found to be 
increased, which could reflect increases in mitochondrial 
membrane permeability rather than muscle damage (27).
Serum lactate showed statistically significant lower 
post-exercise concentrations in horses after treatment with 
Bicarbossilasi®. It is well known that serum lactate accumula-
tion is a consequence of lactate efflux from the muscle during 
intense exercise, following intramuscular anaerobic produc-
tion (5). Results of the present study, confirm that supple-
mentation with thiamine improves glucose metabolism and 
limits lactate accumulation in muscles, enhancing metabolic 
pathways of glucose utilization during exercise. The lower 
serum lactate could be due to the action of TPP at two levels. 
The first is probably the increase of pyruvate metabolism 
thus limiting its accumulation and subsequent activation of 
the anaerobic pathway. The second mechanism could be the 
increase of decarboxylation of alpha-ketoglutarate to form 
succinyl-coenzyme A in the Krebs cycle, since TPP acts as a 
cofactor in this reaction (3).
Previous studies have already shown that the adminis-
tration of supplemental thiamine to athletes, decreases the 
levels of serum lactate during exercise, both in humans and 
horses (18, 21). Current National Research Council recom-
mendation for dietary thiamine is 3 mg/kg of dry matter for 
maintenance and 5 mg/kg dry matter in working horses (34). 
Topliff and collegues demonstrated that horses fed diets with 
the higher dosage of thiamine (28 mg/Kg dry matter) had the 
lowest level of blood lactate compared with horse receiving a 
lower dosage (2 or 4 mg/Kg dry matter) (21). In the present 
study, TPP was administered intravenously at the dosage 
of 1 mg/Kg, twice a day for 7 days and a decrease of serum 
lactate levels was observed. This may make Bicarbossilasi® 
an interesting tool for modulation of energy resources in 
horses without the need for high dosage and long lasting diet 
integration. Because horses receive the appropriate amount of 
thiamine with the diet, and microbial synthesis in the large 
colon has also been demonstrated, diet integration is not 
normally required (35). However, TPP could be parenterally 
administered in horses prone to suffer from lactic acidosis 
when heavy exercise or intense training regimens are planned. 
In human athletes, TPP has been demonstrated to be able 
to decrease blood lactate levels after a single intravenous ad-
ministration (1 mg/Kg) 24 hours before the stress test (18). 
Further studies will be necessary to assess if a single injection 
of TPP before exercise could be effective in preventing lactate 
excess in muscle and blood in horses. Moreover, different 
dosages (e.g. higher dosage) should be tested and compared.
Following high intensity exercise, plasma lactate concen-
trations normally increase, however it starts to decline at a 
linear rate a few minutes after the end of the activity (36). 
We demonstrated that Bicarbossilasi® may reduce plasma 
lactate production during and immediately after the exercise 
but no effect on the lactate rate of decrease during recov-
ery has been demonstrated. This could be explained by the 
above mentioned specific action of thiamine during exercise: 
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breakdown of muscle glycogen providing a greater proportion 
of energy during high intensity exercise (1). Even if TPP 
administration could account for the lower production of 
lactic acid, it had no effect on plasma lactate removal from 
the blood. Furthermore, since training can increase the rate of 
removal of lactic acid from the blood (37), the standardized 
training conditions of the horses included in the study may 
possibly explain the lack of the effect on the disappearance 
of serum blood lactate.
Administration of thiamine in its active form (TPP, thia-
mine pyrophosphate) appears to be able to reduce the blood 
lactate concentration in exercising horses. Since blood lactate 
concentration reflects muscle accumulation (6), administra-
tion of TPP could be a useful tool for preventing or delaying 
the onset of fatigue.
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